Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Cancer

Jozsef L. Varga, Andrew V Schally

Research output: Chapter in Book/Report/Conference proceedingChapter

7 Citations (Scopus)

Abstract

This chapter focuses on potent antagonistic analogs of growth hormone-releasing hormone (GH-RH) in cancer. GHRH antagonists inhibit the growth, tumorigenicity, and metastases of a wide range of human experimental malignancies. GH-RH antagonists bind to pituitary receptors for GH-RH and inhibit the release of GH in vitro and in vivo. The presence of GH-RH ligand was demonstrated in various cancers, suggesting that GH-RH could be an autocrine growth factor. GH-RH antagonists inhibit the growth of various human cancer lines xenografted into nude mice, including breast cancers, prostate cancers, small cell lung carcinomas (SCLC) and non-SCLC, malignant gliomas, renal cell carcinomas, pancreatic cancers, colorectal carcinomas, and lymphomas. These effects of GHRH antagonists could be exerted in part indirectly through inhibition of the secretion of pituitary GH and the resulting reduction in the levels of hepatic IGF-I. However, the principal effect of GH-RH antagonists appears to be the direct suppression of action of the autocrine GHRH and the secretion of IGF-I and IGF-II in tumors, as well as expression of the genes encoding them. These direct effects of GHRH antagonists are exerted on GHRH receptors and their splice variants on tumors. Further development of GH-RH antagonists should lead to potential therapeutic agents for various cancers.

Original languageEnglish
Title of host publicationHandbook of Biologically Active Peptides
PublisherElsevier Inc.
Pages483-489
Number of pages7
ISBN (Print)9780123694423
DOIs
StatePublished - Dec 1 2006

Fingerprint

Growth Hormone-Releasing Hormone
Hormone Antagonists
Neoplasms
Insulin-Like Growth Factor I
Tumors
Prostatic Neoplasms
Cells
Gene encoding
Insulin-Like Growth Factor II
Small Cell Lung Carcinoma
Growth
Pancreatic Neoplasms
Renal Cell Carcinoma
Nude Mice
Non-Small Cell Lung Carcinoma
Glioma
Growth Hormone
Intercellular Signaling Peptides and Proteins
Colorectal Neoplasms
Lymphoma

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Varga, J. L., & Schally, A. V. (2006). Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Cancer. In Handbook of Biologically Active Peptides (pp. 483-489). Elsevier Inc.. https://doi.org/10.1016/B978-012369442-3/50073-8

Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Cancer. / Varga, Jozsef L.; Schally, Andrew V.

Handbook of Biologically Active Peptides. Elsevier Inc., 2006. p. 483-489.

Research output: Chapter in Book/Report/Conference proceedingChapter

Varga, JL & Schally, AV 2006, Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Cancer. in Handbook of Biologically Active Peptides. Elsevier Inc., pp. 483-489. https://doi.org/10.1016/B978-012369442-3/50073-8
Varga JL, Schally AV. Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Cancer. In Handbook of Biologically Active Peptides. Elsevier Inc. 2006. p. 483-489 https://doi.org/10.1016/B978-012369442-3/50073-8
Varga, Jozsef L. ; Schally, Andrew V. / Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Cancer. Handbook of Biologically Active Peptides. Elsevier Inc., 2006. pp. 483-489
@inbook{309a76fd626144bea88435f6c57a3c20,
title = "Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Cancer",
abstract = "This chapter focuses on potent antagonistic analogs of growth hormone-releasing hormone (GH-RH) in cancer. GHRH antagonists inhibit the growth, tumorigenicity, and metastases of a wide range of human experimental malignancies. GH-RH antagonists bind to pituitary receptors for GH-RH and inhibit the release of GH in vitro and in vivo. The presence of GH-RH ligand was demonstrated in various cancers, suggesting that GH-RH could be an autocrine growth factor. GH-RH antagonists inhibit the growth of various human cancer lines xenografted into nude mice, including breast cancers, prostate cancers, small cell lung carcinomas (SCLC) and non-SCLC, malignant gliomas, renal cell carcinomas, pancreatic cancers, colorectal carcinomas, and lymphomas. These effects of GHRH antagonists could be exerted in part indirectly through inhibition of the secretion of pituitary GH and the resulting reduction in the levels of hepatic IGF-I. However, the principal effect of GH-RH antagonists appears to be the direct suppression of action of the autocrine GHRH and the secretion of IGF-I and IGF-II in tumors, as well as expression of the genes encoding them. These direct effects of GHRH antagonists are exerted on GHRH receptors and their splice variants on tumors. Further development of GH-RH antagonists should lead to potential therapeutic agents for various cancers.",
author = "Varga, {Jozsef L.} and Schally, {Andrew V}",
year = "2006",
month = "12",
day = "1",
doi = "10.1016/B978-012369442-3/50073-8",
language = "English",
isbn = "9780123694423",
pages = "483--489",
booktitle = "Handbook of Biologically Active Peptides",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Cancer

AU - Varga, Jozsef L.

AU - Schally, Andrew V

PY - 2006/12/1

Y1 - 2006/12/1

N2 - This chapter focuses on potent antagonistic analogs of growth hormone-releasing hormone (GH-RH) in cancer. GHRH antagonists inhibit the growth, tumorigenicity, and metastases of a wide range of human experimental malignancies. GH-RH antagonists bind to pituitary receptors for GH-RH and inhibit the release of GH in vitro and in vivo. The presence of GH-RH ligand was demonstrated in various cancers, suggesting that GH-RH could be an autocrine growth factor. GH-RH antagonists inhibit the growth of various human cancer lines xenografted into nude mice, including breast cancers, prostate cancers, small cell lung carcinomas (SCLC) and non-SCLC, malignant gliomas, renal cell carcinomas, pancreatic cancers, colorectal carcinomas, and lymphomas. These effects of GHRH antagonists could be exerted in part indirectly through inhibition of the secretion of pituitary GH and the resulting reduction in the levels of hepatic IGF-I. However, the principal effect of GH-RH antagonists appears to be the direct suppression of action of the autocrine GHRH and the secretion of IGF-I and IGF-II in tumors, as well as expression of the genes encoding them. These direct effects of GHRH antagonists are exerted on GHRH receptors and their splice variants on tumors. Further development of GH-RH antagonists should lead to potential therapeutic agents for various cancers.

AB - This chapter focuses on potent antagonistic analogs of growth hormone-releasing hormone (GH-RH) in cancer. GHRH antagonists inhibit the growth, tumorigenicity, and metastases of a wide range of human experimental malignancies. GH-RH antagonists bind to pituitary receptors for GH-RH and inhibit the release of GH in vitro and in vivo. The presence of GH-RH ligand was demonstrated in various cancers, suggesting that GH-RH could be an autocrine growth factor. GH-RH antagonists inhibit the growth of various human cancer lines xenografted into nude mice, including breast cancers, prostate cancers, small cell lung carcinomas (SCLC) and non-SCLC, malignant gliomas, renal cell carcinomas, pancreatic cancers, colorectal carcinomas, and lymphomas. These effects of GHRH antagonists could be exerted in part indirectly through inhibition of the secretion of pituitary GH and the resulting reduction in the levels of hepatic IGF-I. However, the principal effect of GH-RH antagonists appears to be the direct suppression of action of the autocrine GHRH and the secretion of IGF-I and IGF-II in tumors, as well as expression of the genes encoding them. These direct effects of GHRH antagonists are exerted on GHRH receptors and their splice variants on tumors. Further development of GH-RH antagonists should lead to potential therapeutic agents for various cancers.

UR - http://www.scopus.com/inward/record.url?scp=58149481977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149481977&partnerID=8YFLogxK

U2 - 10.1016/B978-012369442-3/50073-8

DO - 10.1016/B978-012369442-3/50073-8

M3 - Chapter

AN - SCOPUS:58149481977

SN - 9780123694423

SP - 483

EP - 489

BT - Handbook of Biologically Active Peptides

PB - Elsevier Inc.

ER -